Myocardial Ischemia Without Obstructive Coronary Stenoses
1 other identifier
observational
600
1 country
1
Brief Summary
Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders. This prospective study has been created in order to provide knowledge in the field of non-obstructive coronary artery disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 8, 2017
CompletedFirst Submitted
Initial submission to the registry
March 25, 2021
CompletedFirst Posted
Study publicly available on registry
April 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
ExpectedApril 26, 2021
April 1, 2021
8.2 years
March 25, 2021
April 23, 2021
Conditions
Outcome Measures
Primary Outcomes (3)
Patient-oriented composite outcome
Incidence of a patient-oriented composite outcome, a composite of any death, nonfatal myocardial infarction, any ischemia-driven revascularization or hospitalization due to unstable angina pectoris
Up to 5 years
Vessel-oriented composite outcome
Incidence of a vessel-oriented composite outcome, a composite of cardiac death, target-vessel related myocardial infarction or target-vessel revascularization
Up to 5 years
Patient symptoms burden
Change in the Seattle questionnaire of angina scoring, associated to stratified medical treatment. Minimum is 0 and maximum is 100 and lower scores indicate worse outcome
Up to 12 months
Secondary Outcomes (6)
Cumulative incidence of any death
Up to 5 years
Cumulative incidence of cardiac death
Up to 5 years
Cumulative incidence of nonfatal myocardial infarction
Up to 5 years
Cumulative incidence of ischemia-driven revascularization
Up to 5 years
Safety of invasive comprehensive coronary functional testing with adenosine and acetylcholine
During procedure
- +1 more secondary outcomes
Other Outcomes (13)
Resting and hyperemic mean aortic pressure (mmHg)
During procedure
Resting and hyperemic mean intracoronary distal pressure (mmHg)
During procedure
Resting and hyperemic mean coronary flow (mean transit time or cms/sec)
During procedure
- +10 more other outcomes
Study Arms (1)
Myocardial ischemia without obstructive coronary stenosis
Interventions
Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
Eligibility Criteria
The target population consists of patients with clinically indicated invasive physiological measures of coronary pressure and flow with adenosine and acetylcholine for the assessment of myocardial ischemia.
You may qualify if:
- Written informed consent available.
- Age ≥ 18 years.
- Patient eligible for invasive physiological assessment with adenosine and / or acetylcholine.
You may not qualify if:
- Hemodynamic instability.
- Anticipated technical issues for physiology wire measurements.
- Culprit vessel of acute coronary syndrome
- Contraindications for adenosine administration.
- Contraindications for acetylcholine test.
- Reduced life expectancy (less than 1 year).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Clinico San Carlos
Madrid, 28040, Spain
Related Publications (2)
Mejia-Renteria H, Shabbir A, Nunez-Gil IJ, Macaya F, Salinas P, Tirado-Conte G, Nombela-Franco L, Jimenez-Quevedo P, Gonzalo N, Fernandez-Ortiz A, Escaned J. Feasibility and Improved Diagnostic Yield of Intracoronary Adenosine to Assess Microvascular Dysfunction With Bolus Thermodilution. J Am Heart Assoc. 2024 Nov 19;13(22):e035404. doi: 10.1161/JAHA.124.035404. Epub 2024 Nov 7.
PMID: 39508144DERIVEDMejia-Renteria H, Wang L, Chipayo-Gonzales D, van de Hoef TP, Travieso A, Espejo C, Nunez-Gil IJ, Macaya F, Gonzalo N, Escaned J. Angiography-derived assessment of coronary microcirculatory resistance in patients with suspected myocardial ischaemia and non-obstructive coronary arteries. EuroIntervention. 2023 Apr 3;18(16):e1348-e1356. doi: 10.4244/EIJ-D-22-00579.
PMID: 36534493DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hernan Mejia-Renteria, MD, PhD
Department of Cardiology, Hospital Clinico San Carlos
- PRINCIPAL INVESTIGATOR
Javier Escaned, MD, PhD
Department of Cardiology, Hospital Clinico San Carlos
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 25, 2021
First Posted
April 1, 2021
Study Start
November 8, 2017
Primary Completion
December 31, 2025
Study Completion (Estimated)
December 31, 2030
Last Updated
April 26, 2021
Record last verified: 2021-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, CSR
- Time Frame
- Throughout the development of the study
The study contemplates the possibility of sharing data with other researchers who have similar objectives. IPD to be shared includes demographic data, vessel characteristics, invasive coronary physiology data and outcome measures, appropriately anonymized.